Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735

Viking Therapeutics has signed a multi-year manufacturing agreement with CordenPharma to support commercialization of its obesity drug candidate VK273512.

The deal secures dedicated capacity for multi-ton annual supply of VK2735 active pharmaceutical ingredient (API)1.

CordenPharma will provide fill/finish capacity for 100 million annual autoinjector supply and additional 100 million annual vial/syringe supply for the subcutaneous formulation12.

The agreement also covers manufacturing capacity for over one billion oral VK2735 tablets annually24.

Viking will make prepayments totaling $150 million to CordenPharma between 2025-2028 in exchange for dedicated manufacturing capacity12.

VK2735 is a dual agonist of GLP-1 and GIP receptors being developed for obesity and metabolic disorders24.

Viking plans to initiate Phase 3 development of the subcutaneous formulation of VK2735 in Q2 202524.

The partnership leverages CordenPharma's expertise in peptide manufacturing, sterile injectables, and oral solid dosage production47.

This agreement aims to support what Viking anticipates will be significant commercial demand for VK273514.

The collaboration is expected to streamline Viking's manufacturing process and improve supply chain efficiency for VK273524.

Sources:

1. https://cordenpharma.com/how-we-deliver/technology-platforms/injectables-platform/

2. https://www.prnewswire.com/news-releases/viking-therapeutics-signs-broad-manufacturing-agreement-with-cordenpharma-to-support-commercialization-of-vk2735-302397853.html

4. https://www.pharmexec.com/view/viking-therapeutics-cordenpharma-multi-year-deal-commercialize-vk2735-obesity-metabolic-disorders

7. https://www.prnewswire.com/news-releases/cordenpharma-and-viking-therapeutics-sign-long-term-strategic-partnership-for-integrated-supply-of-glp-1-peptides-injectables-and-oral-formulations-302397563.html